|
polyps
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Polyp tissues exhibited significantly increased GPR17 expression relative to uncinate process tissues from CRSsNP patients, or healthy controls (P=0.0012 and P<0.0001, respectively).
|
29161055 |
2018 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
GPR17 is believed to be a novel target for the development of new therapeutic approaches to human stroke and multiple sclerosis.
|
28223679 |
2017 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
GPR17 is believed to be a novel target for the development of new therapeutic approaches to human stroke and multiple sclerosis.
|
28223679 |
2017 |
|
Cerebrovascular accident
|
0.040 |
AlteredExpression
|
group |
BEFREE |
GPR17, a receptor transiently expressed on early OPCs, has emerged as a target to implement stroke repair through stimulation of OPC maturation.
|
28594400 |
2017 |
|
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Cerebral Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
GPR17 mediates microglial inflammation in the chronic phase of cerebral ischemia and regulates allergic pulmonary inflammation.
|
30036769 |
2018 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
Against this background, we have examined the neuroprotective efficacy of arginine-rich protamine peptides, a cyclic (R12-c) poly-arginine peptide and a R22 poly-arginine peptide, as well as arginine peptides containing tryptophan or other amino acids (phenylalanine, tyrosine, glycine or leucine) in in vitro glutamic acid excitotoxicity and in vivo rat permanent middle cerebral artery occlusion models of stroke.
|
28523591 |
2017 |
|
Middle Cerebral Artery Occlusion
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Assessment of the Neuroprotective Effects of Arginine-Rich Protamine Peptides, Poly-Arginine Peptides (R12-Cyclic, R22) and Arginine-Tryptophan-Containing Peptides Following In Vitro Excitotoxicity and/or Permanent Middle Cerebral Artery Occlusion in Rats.
|
28523591 |
2017 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on previously reported GPR17 activation by emergency signals (e.g., Stromal Derived Factor-1), we propose that a marked inflammatory milieu, such as that reproduced in EAE, induces GPR17 overactivation resulting in impaired downregulation, untimely and prolonged permanence in OPCs, leading, in turn, to differentiation blockade.
|
29424466 |
2018 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
By contrast, accompanying several chromosome losses, germline heterozygous mutations in the tumor suppressor genes, mucin 6, oligomeric mucus/gel-forming (<i>MUC6</i>), and G protein-coupled receptor 17 (<i>GPR17</i>) showed loss of heterozygosity in the two tumors, or in T2, respectively.
|
29725435 |
2018 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
G Protein-coupled Receptor 17 (GPR17) is phylogenetically related to the purinergic receptors emerged as a potential drug target for multiple sclerosis, Parkinson disease, Alzheimer disease and cancer.
|
28827203 |
2018 |
|
Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we used a swine model of myocardial infarction (MI) to test preliminarily a novel gene therapy for heart failure based on delivery of the human RNR enzyme complex under the control of a cardiac-specific promoter via an adeno-associated virus serotype 6 vector--designated as BB-R12.
|
25876005 |
2015 |
|
Middle Cerebral Artery Occlusion
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, to univocally define the spatiotemporal changes and final fate of GPR17-expressing OPCs, we induced ischemia by middle cerebral artery occlusion (MCAo) in reporter GPR17iCreER<sup>T2</sup>:CAG-eGreen florescent protein (GFP) mice, in which, upon tamoxifen treatment, cells expressing GPR17 become green and traceable for their entire life.
|
28594400 |
2017 |
|
Cerebral Infarction
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, being GPR17 completely downregulated in myelin-producing oligodendrocytes, its actual role in determining the final fate of OPCs after cerebral ischemia is still uncertain.
|
28594400 |
2017 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
In subsequent years, evidence of GPR17 key role in oligodendrogenesis and myelination has highlighted it as a "model receptor" for new therapies in demyelinating and neurodegenerative diseases.
|
28828731 |
2017 |
|
Brain Infarction
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Magnetic Resonance Imaging in living mice showed that the in vivo pharmacological or biotechnological knock down of GPR17 markedly prevents brain infarct evolution, suggesting GPR17 as a mediator of neuronal death at this early ischemic stage.
|
18974869 |
2008 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Mean time from RT to cancer diagnosis 89±70 months (R, 12-276).
|
29757570 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Mean time from RT to cancer diagnosis 89±70 months (R, 12-276).
|
29757570 |
2018 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our lead thioaptamer, R12-2, targets the RNase H domain of the HIV-1 reverse transcriptase (RT) and inhibits viral infection in U373-MAGI-CCR5 cells.
|
16631118 |
2006 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Our studies suggest that R-12 displayed potent inhibitory effect on cell growth and colony formation, which is associated with delaying S phase progression by inhibiting DNA synthesis in human hepatoma cancer BEL-7402, SMMC-7721 and ZIP-177 cells.
|
31171403 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Our studies suggest that R-12 displayed potent inhibitory effect on cell growth and colony formation, which is associated with delaying S phase progression by inhibiting DNA synthesis in human hepatoma cancer BEL-7402, SMMC-7721 and ZIP-177 cells.
|
31171403 |
2019 |
|
Brain Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |